Clinical trials: Hypertension, Essential
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Essential Hypertension
Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts.
- Trial name
- NCT02062645
- Testing
- amlodipine/valsartan
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Hypertension
LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the…
- Trial name
- NCT00496834
- Testing
- losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ)
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Essential Hypertension
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy.
- Trial name
- NCT01631227
- Testing
- Eprosartan, Eprosartan Mesylate
- Where
- 38 sites in Germany, Russia and 1 more
- Volunteers
- 665 people
- Sponsor
- Abbott
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis
Hypertension
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
- Trial name
- NCT00415623
- Testing
- Amlodipine
- Where
- 14 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Systolic, Cerebrovascular Disease
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of…
- Trial name
- NCT01650402
- Testing
- Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- UConn Health
Hypertension
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.
- Trial name
- NCT00760214
- Testing
- Azilsartan medoxomil, Ramipril
- Where
- 72 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 885 people
- Sponsor
- Takeda
Hypertension, Hypertension,Essential
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
- Trial name
- NCT03503773
- Testing
- Alcohol
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 350 people
- Sponsor
- Ablative Solutions, Inc.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Hypertension
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and < 110 mmHg).
- Trial name
- NCT00402103
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of…
- Trial name
- ACQUIRE (NCT00705575)
- Testing
- Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg)
- Where
- 8 sites in United States, Argentina and 6 more
- Volunteers
- 688 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.
- Trial name
- NCT02277691
- Testing
- TAK-536TCH tablet, TAK-536CCB tablet, HCTZ 12.5 mg tablet
- Where
- 38 sites in Japan
- Volunteers
- 341 people
- Sponsor
- Takeda